PRKDC and peripheral arterial disease: Our previous preclinical work showed synthetic lethality of a multi‐pronged DNA damage repair interference strategy using the PARPi olaparib, ATR inhibitor VE‐822, and DNA‐PK inhibitor CC‐115 (termed PAD) in ATM deficiency.